Bevacizumab Plus Standard-of-Care Treatment After Progression in Advanced Non–Small Cell Lung Cancer

This randomized clinical trial assesses the efficacy and safety of continuous bevacizumab treatment plus standard of care vs standard of care alone beyond first progression in patients with non–small cell lung cancer.

https://ift.tt/2onnstG